Effect of aging on 6-keto-PGF1 alpha levels in normotensive and essential hypertensive males.

Prostacyclin (PGI2) is produced in the vessel wall and acts as a vasodilator hormone. Measurement of plasma 6-keto-PGF1 alpha is considered to be an index of PGI2 production. In the present study the effects of aging on the plasma 6-keto-PGF1 alpha levels were studied in 64 normotensive and 48 essential hypertensive males. The subjects were divided into 3 groups, i.e., young (24-39 years), middle-aged (40-55 years) and elderly (over 56 years) groups. Plasma 6-keto-PGF1 alpha was measured by specific radioimmunoassay after silicic acid column chromatographic purification. The 6-keto-PGF1 alpha levels were lower in elderly normotensive males (10.3 +/- 1.4 pg/ml, mean +/- SE, n = 12) than in normotensive young males (15.3 +/- 2.3, n = 30, p less than 0.05). The plasma 6-keto-PGF1 alpha levels in hypertensive elderly males (10.6 +/- 1.3 pg/ml, n = 10) is lower than in hypertensive young males (19.8 +/- 2.2, n = 17, p less than 0.01). These results indicate that the plasma 6-keto-PGF1 alpha levels decreased with age in both normotensive and hypertensive groups. Thus, PGI2 production may decrease with age.

[1]  T. Ogihara,et al.  Release of prostaglandin I2 from hog kidney by propranolol. , 1982, Prostaglandins, leukotrienes, and medicine.

[2]  E. Christ-Hazelhof,et al.  Prostacyclin is not a circulating hormone. , 1981, Prostaglandins.

[3]  P. Goldman,et al.  Effect of Salt on Prostaglandin Metabolism in Hypertension‐Prone and ‐Resistant Dahl Rats , 1981, Hypertension.

[4]  S. Murota,et al.  Age-related decrease in prostacyclin biosynthetic activity in rat aortic smooth muscle cells. , 1980, Biochimica et biophysica acta.

[5]  N. Hollenberg,et al.  Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. , 1980, The Journal of clinical investigation.

[6]  J. Botha,et al.  Enhanced release of a 'prostacyclin-like' substance from aortic strips of spontaneously hypertensive rats. , 1980, Prostaglandins.

[7]  J. Botha,et al.  Enhanced release of 'PGI2-like' substance in experimental hypertension. , 1979, Prostaglandins and medicine.

[8]  J. Elder,et al.  VASCULAR PROSTACYCLIN MAY BE REDUCED IN DIABETES IN MAN , 1979, The Lancet.

[9]  A. M. Lefer,et al.  Antibodies which antagonise the effects of prostacyclin , 1978, Nature.

[10]  M. Carrara,et al.  Enhanced formation of PGI2, a potent hypotensive substance, by aortic rings and homogenates of the spontaneously hypertensive rat. , 1978, Prostaglandins.

[11]  H. White,et al.  Synthesis of prostaglandin 6-keto F1alpha by cultured aortic smooth muscle cells and stimulation of its formation in a coupled system with platelet lysates. , 1978, Prostaglandins.

[12]  J. Vane,et al.  Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. , 1977, Thrombosis research.

[13]  J. Vane,et al.  A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. , 1976, Prostaglandins.

[14]  C. Patrono,et al.  Evidence for a direct stimulatory effect of prostacyclin on renin release in man. , 1982, The Journal of clinical investigation.

[15]  J. O'grady,et al.  Clinical pharmacology of prostacyclin , 1981 .